Key result
Cardiovascular device-induced shear stress and inflammation drive platelet activation and thrombosis, which can be evaluated with novel modeling and targeted beyond conventional antiplatelet drugs.
Summarizes the biomechanical and inflammatory mechanisms of cardiovascular device-related platelet activation and highlights novel in vitro/in vivo modeling techniques and therapeutic targets beyond conventional antiplatelet therapy to optimize device design and patient outcomes.
Answers are grounded in this paper and cite their sources.
Device thrombosis modeling may refine engineering; leaves open targeted therapies beyond antiplatelets pending prospective validation.
T he objectives of the 2011 Platelet Colloquium were to gain a better understanding of the role of platelets and inflammatory cells in the response to cardiovascular deviceassociated injury; to describe the relationship between cardiac devices, shear stress, and alterations in platelet biology and function; and to review evidence derived from in vitro, in vivo, and clinical investigations supporting therapies to modify platelet and inflammatory cell-associated responses to device-related injury.
No takes yet. Share an insight, caveat, or question.
Rowley et al. (2012) conducted a review in Cardiovascular device-associated vascular injury and thrombosis. Cardiovascular devices and antiplatelet/anti-inflammatory therapies was evaluated. Cardiovascular device-induced shear stress and inflammation drive platelet activation and thrombosis, which can be evaluated with novel modeling and targeted beyond conventional antiplatelet drugs.
Synapse has enriched 10 related papers. Consider them for comparative context: